Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 2
2005 4
2006 5
2007 2
2008 4
2009 2
2010 2
2011 2
2012 9
2013 7
2014 5
2015 4
2016 6
2017 6
2018 12
2019 8
2020 11
2021 14
2022 14
2023 6
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus.
Grannes H, Ueland T, Simeone P, Liani R, Guagnano MT, Aukrust P, Michelsen AE, Birkeland K, di Castelnuovo A, Cipollone F, Consoli A, Halvorsen B, Gregersen I, Santilli F. Grannes H, et al. Among authors: consoli a. Cardiovasc Diabetol. 2024 Apr 29;23(1):146. doi: 10.1186/s12933-024-02237-8. Cardiovasc Diabetol. 2024. PMID: 38685051 Free PMC article.
Oral or injectable semaglutide for the management of type 2 diabetes in routine care: A multicentre observational study comparing matched cohorts.
Fadini GP, Bonora BM, Ghiani M, Anichini R, Melchionda E, Fattor B, Fazion S, Meregalli G, Giaccari A, Avogaro A, Consoli A; GLIMPLES study investigators. Fadini GP, et al. Among authors: consoli a. Diabetes Obes Metab. 2024 Mar 13. doi: 10.1111/dom.15554. Online ahead of print. Diabetes Obes Metab. 2024. PMID: 38477183
Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk.
Fadini GP, Longato E, Morieri ML, Del Prato S, Avogaro A, Solini A; DARWIN-Renal Study Investigators. Fadini GP, et al. Lancet Reg Health Eur. 2024 Feb 1;38:100847. doi: 10.1016/j.lanepe.2024.100847. eCollection 2024 Mar. Lancet Reg Health Eur. 2024. PMID: 38328413 Free PMC article.
La territorializzazione del farmaco in epoca di PNRR: prospettive, opportunità e spunti di riflessione da un panel di esperti.
Marata AM, Marrocco W, Arcangeli E, Battistini M, Buzzetti G, Candido R, Casadei G, Cattel F, Cavaliere A, Consoli A, Corrao G, Didoni G, Di Gesù M, Giovanzana A, Lenzi M, Medaglia M, Meloncelli M, Palcic S, Pani M, Patarnello F, Pria E, Scaduto D, Tozzi V, Zibellini M, Crovato E. Marata AM, et al. Among authors: consoli a. Glob Reg Health Technol Assess. 2022 Dec 5;9:155-158. doi: 10.33393/grhta.2022.2495. eCollection 2022 Jan-Dec. Glob Reg Health Technol Assess. 2022. PMID: 36628310 Free PMC article. Italian.
117 results